Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CUE logo CUE
Upturn stock ratingUpturn stock rating
CUE logo

Cue Biopharma (CUE)

Upturn stock ratingUpturn stock rating
$0.74
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/27/2025: CUE (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

4 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $4

1 Year Target Price $4

Analysts Price Target For last 52 week
$4Target price
Low$0.45
Current$0.74
high$1.99

Analysis of Past Performance

Type Stock
Historic Profit -58.88%
Avg. Invested days 23
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/27/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 56.43M USD
Price to earnings Ratio -
1Y Target Price 4
Price to earnings Ratio -
1Y Target Price 4
Volume (30-day avg) 4
Beta 1.42
52 Weeks Range 0.45 - 1.99
Updated Date 06/30/2025
52 Weeks Range 0.45 - 1.99
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.58

Earnings Date

Report Date 2025-06-05
When Before Market
Estimate -0.28
Actual -0.1279

Profitability

Profit Margin -
Operating Margin (TTM) -2921.38%

Management Effectiveness

Return on Assets (TTM) -67.62%
Return on Equity (TTM) -221.66%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 45347478
Price to Sales(TTM) 7.06
Enterprise Value 45347478
Price to Sales(TTM) 7.06
Enterprise Value to Revenue 5.67
Enterprise Value to EBITDA -1.76
Shares Outstanding 75349904
Shares Floating 75083896
Shares Outstanding 75349904
Shares Floating 75083896
Percent Insiders 0.35
Percent Institutions 15.19

Analyst Ratings

Rating 2
Target Price 4
Buy 2
Strong Buy 2
Buy 2
Strong Buy 2
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Cue Biopharma

stock logo

Company Overview

overview logo History and Background

Cue Biopharma, founded in 2011, is a clinical-stage biopharmaceutical company focused on developing a novel class of injectable biologics to selectively engage and modulate the human immune system directly within the body to fight cancer and autoimmune diseases. Their Immuno-STAT (Selective Targeting and Activation of T cells) platform is designed to harness the body's natural defenses.

business area logo Core Business Areas

  • Immuno-STAT Platform: Development of biologics using the Immuno-STAT platform to selectively activate and modulate T cells for cancer and autoimmune diseases. Their lead product candidate is CUE-101.

leadership logo Leadership and Structure

The leadership team consists of Ayacut Gokirmak (CEO), Kerri-Ann Millar (Chief Financial Officer), and other experienced executives in the biopharmaceutical industry. The company has a board of directors that oversees its strategic direction.

Top Products and Market Share

overview logo Key Offerings

  • CUE-101: CUE-101 is Cue Biopharma's lead drug candidate, an Immuno-STAT biologic designed to selectively activate and expand tumor-specific CD8+ T cells to target HPV16-driven cancers. It is currently in clinical trials. Market share data and specific revenue figures are not publicly available as it is still in the development phase. Competitors include companies developing immunotherapies for HPV-driven cancers, such as Merck (Keytruda) and Bristol Myers Squibb (Opdivo), although their mechanisms are different.
  • CUE-102 & CUE-103: CUE-102 & CUE-103 are earlier stage Immuno-STAT biologics targeting other cancers. No market share or revenue data is available as they are in pre-clinical and early clinical development. Competitors are similar to those for CUE-101.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is highly competitive, with significant investment in immunotherapy and targeted therapies. The cancer immunotherapy market is experiencing strong growth driven by advances in understanding the immune system and the development of novel therapeutic approaches.

Positioning

Cue Biopharma is positioned as an innovator in the field of T cell modulation. Its Immuno-STAT platform offers a unique approach compared to traditional checkpoint inhibitors and cell therapies. The competitive advantage lies in selective T cell activation within the body, aiming for improved efficacy and reduced toxicity.

Total Addressable Market (TAM)

The TAM for cancer immunotherapy is estimated to be in the tens of billions of dollars annually. Cue Biopharma is targeting specific cancers, such as HPV-driven cancers, which represent a significant portion of the overall TAM. Their position is in the early stages of commercialization and gaining market share would heavily depend on clinical trial success and regulatory approvals.

Upturn SWOT Analysis

Strengths

  • Novel Immuno-STAT platform
  • Targeted T cell activation
  • Potential for improved efficacy and safety
  • Strong scientific team

Weaknesses

  • Limited clinical data
  • Early stage of development
  • Reliance on clinical trial success
  • High cash burn rate

Opportunities

  • Expanding clinical trials to new indications
  • Partnerships with larger pharmaceutical companies
  • Positive clinical trial results driving market adoption
  • Advancements in understanding of the immune system

Threats

  • Clinical trial failures
  • Competition from established immunotherapy players
  • Regulatory hurdles
  • Financing challenges

Competitors and Market Share

competitor logo Key Competitors

  • MRK
  • BMY
  • GILD

Competitive Landscape

Cue Biopharma's competitive advantage lies in its novel Immuno-STAT platform, offering targeted T cell activation. However, it faces significant competition from established players with approved immunotherapies and larger resources.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is reflected in preclinical and clinical advancements, which have been slow with the amount of funding available

Future Projections: Future projections depend on clinical trial outcomes, regulatory approvals, and market adoption. Analyst estimates are subject to change and require financial data subscriptions.

Recent Initiatives: Recent initiatives include advancing CUE-101 through clinical trials and expanding the pipeline with new Immuno-STAT candidates.

Summary

Cue Biopharma is an early-stage company with a promising Immuno-STAT platform, but faces significant challenges. Clinical trial successes are vital for its growth trajectory. Competition from established players and financial constraints are key considerations. Positive clinical data and strategic partnerships could improve its prospects.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Analyst Reports (subscription required)
  • Industry Publications

Disclaimers:

The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on independent research and professional consultation. Financial data is subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Cue Biopharma

Exchange NASDAQ
Headquaters Boston, MA, United States
IPO Launch date 2018-01-02
CEO, Interim Principal Financial and Accounting Officer & Director Mr. Daniel R. Passeri J.D., M.Sc.
Sector Healthcare
Industry Biotechnology
Full time employees 41
Full time employees 41

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinical trial to treat HPV+ recurrent metastatic, or head and neck squamous cell carcinoma in second line, and beyond patients as a monotherapy, as well as in phase 1b clinical trial for the treatment of head and neck squamous cell carcinoma as a first line, therapy in combination with standard of care KEYTRUDA; and CUE-102, which is in phase 1b clinical trial as a monotherapy in late line recurrent metastatic WT1+ colorectal, gastric, ovarian, and pancreatic cancer. It has collaboration agreements with LG Chem, Ltd. for the development of CUE-101 and CUE-102 Immuno-STATs; collaboration and option agreement with Ono Pharmaceutical Co., Ltd to development and commercialization rights for CUE-401; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.